Deal Watch: Merck KGAA Boosts Pharma Unit’s Reach And Capabilities With Sigma-Aldrich Buy
Executive Summary
Acorda buys Civitas and its Parkinson’s candidate for $525 million, ending the latter’s intent to go public. Pharmacyclics and Servier unwind their 2009 agreement to co-develop oncology drug abexinostat.
You may also be interested in...
Pfizer Seizes Long-Term Immuno-Oncology Opportunity With Merck Deal
Pfizer partnered with Germany’s Merck KGAA to develop and commercialize an anti-PD-L1 checkpoint inhibitor in clinical development, paying $850 million upfront to catch up to the competition.
Merck KGaA Buys Sigma-Aldrich To Boost Lab Business, Expand Footprint
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Can Merck Serono Bounce Back?
Merck KGAA’s $13 billion acquisition of Serono in 2006 created an unwieldy pharmaceutical organization further hobbled by expensive clinical setbacks. Seven years later, driven by new leadership, it is in the midst of an overdue transformation.